IMFINZI® Maintenance - Small Cell Lung Cancer
IMFINZI® (Durvalumab) Maintenance treatment - for Extensive Stage Small Cell Lung Cancer
Treatment started after completion of 4 cycles of chemoimmunotherapy and continued until disease progression or unacceptable toxicity. Monitor closely for immune mediated end organ damage such as Pneumonitis, Colitis, Hepatitis, Endocrinopathies and Nephritis.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
IMFINZI® (Durvalumab) IV 1500 mg D1 q28 NSS 250 cc 60 minutes